Companies / NEU

NEUREN PHARMACEUTICALS LIMITED

ASX:NEUPharmaceuticals, Biotechnology & Life Sciences
126.8M shares on issueASX (delayed) · as of 28 July 2026$16.70price · delayed$2.09Bmarket cap · indicative
A
Dilution grade

2% of shares in the money

Cash runwayno data — no longer lodges quarterly cash reports (4C/5B)
Share-count growth (24m)-0.8%
Raise cadence (24m)0 cash raises
Options & rights overhang2.2% of shares
In-the-money supply1.9% of shares
Pending proposed issuesnone

NEUREN PHARMACEUTICALS LIMITED's ordinary share count was 127M as of June 2026, a decline of 0.8% between June 2024 and June 2026. There were no capital raises in the 24-month window. Options and rights on issue could convert into 3M new shares, equal to 2.2% of the current share count, of which 2% are in the money at the current share price; the nearest expiry is February 2029. The company no longer lodges quarterly cash reports (Appendix 4C/5B), so no quarterly cash balance or funding-runway figure is disclosed. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
2.2%
Max option dilution
1.9%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · stale filings

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 126.8M per ASX (delayed) (28 July 2026).
126.8M128.0M129.2MDec 24Sept 25July 26

Cash runway

—
stale Last quarterly cash report is more than 12 months old (quarter ended 31 Mar 2024) — runway is not computed from stale filings.
$318.6M available cash reported at 31 Mar 2024.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2024.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
18 June 20262A · quoted issueNEU : ORDINARY FULLY PAID126.8MAppendix 2A
1 June 20263G · unquotedNEU : ORDINARY FULLY PAID126.4MAppendix 3G
1 June 20263H · cancellationNEU : ORDINARY FULLY PAID126.3MAppendix 3H
11 May 20263H · cancellationNEU : ORDINARY FULLY PAID126.4MAppendix 3H
10 Apr 20263H · cancellationNEU : ORDINARY FULLY PAID126.5MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

2.2%
Total overhang · of current shares
1.9%
In the money · at current price
2.7M
Potential new shares
Feb 2029
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
5 Mar 2026Joseph BasileBuy12k—$152k3Y notice
8 Sept 2025Jonathan PilcherSell———3Y notice
22 July 2025Jonathan PilcherBuy1.5M—$2.8M3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Neuren highlights participation in PMSF Family Conference
28 June 2026$PDAYBU recommended for approval in the European Union
18 June 2026Application for quotation of securities - NEU
1 June 2026Notification of cessation of securities - NEU
1 June 2026Notification regarding unquoted securities - NEU
27 May 2026Results of Meeting
27 May 2026$PAGM Chair Address & CEO Presentation
13 May 2026Update - Notification of buy-back - NEU
12 May 2026Launch of Investor Hub to enhance shareholder engagement
11 May 2026Notification of cessation of securities - NEU
11 May 2026Update - Notification of buy-back - NEU
10 May 2026Update - Notification of buy-back - NEU
6 May 2026$PQ1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
6 May 2026Update - Notification of buy-back - NEU
28 Apr 2026Update - Notification of buy-back - NEU
24 Apr 2026Virtual AGM online guide
24 Apr 2026Notice of Annual General Meeting/Proxy Form
24 Apr 2026Appendix 4G
24 Apr 20262025 Annual Report to shareholders
20 Apr 2026Update - Notification of buy-back - NEU

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.